Semaglutide reduces heart risks in overweight and obese individuals without diabetes

By Vijay Kumar MalesuReviewed by Susha Cheriyedath, M.Sc.Jun 26 2024 In a recent study published in the journal Diabetes Care, a group of researchers evaluated the cardiovascular effects of semaglutide by baseline glycated hemoglobin and change in HbA1c in a prespecified analysis of Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity .

About the study The present SELECT trial was a multicenter, randomized, double-blind, placebo-controlled study assessing the effect of weekly 2.4 mg semaglutide versus placebo on cardiovascular events in individuals with cardiovascular disease and overweight or obesity without diabetes. Approved by regulatory and ethics authorities, the trial required participants to be at least 45 years old with a body mass index of 27 kg/m² or higher and established cardiovascular disease.

Study results In the trial, 17,604 participants were randomized, with 8,803 receiving semaglutide and 8,801 placebo. Participants were evenly distributed across baseline HbA1c subgroups: 33.5% had HbA1c <5.7%, 34.6% had HbA1c between 5.7% and <6.0%, and 31.9% had HbA1c between 6.0% and <6.5%. Baseline characteristics were similar across treatment groups within each HbA1c subgroup.

Source: Healthcare Press (healthcarepress.net)

Heart Semaglutide Cardiovascular Disease Coronary Artery Disease Fasting Glucagon Glucose Glycated Hemoglobin Hba1c Heart Failure Hemoglobin Metformin Mortality Obesity Peripheral Artery Disease Placebo Prediabetes Stroke Thiazolidinediones

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024Novo Nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions of the American Diabetes Association (ADA).
Source: NewsMedical - 🏆 19. / 71 Read more »

Semaglutide leads to greater weight loss in women than men with heart failure, improves symptomsSemaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.
Source: medical_xpress - 🏆 101. / 51 Read more »

Semaglutide provides double benefit for women with heart failureSemaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.
Source: NewsMedical - 🏆 19. / 71 Read more »

Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch studyA recent study from the PIONEER REAL Netherlands trial demonstrated that oral semaglutide effectively manages type 2 diabetes and supports weight loss in adults.
Source: NewsMedical - 🏆 19. / 71 Read more »

Taking semaglutide once weekly may lower the chances of kidney disease, says studyThe effects of semaglutide (administered once weekly) on the outcomes of kidney disease.
Source: NewsMedical - 🏆 19. / 71 Read more »

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settingsSemaglutide and its effects on glycemic control, body weight (BW), and tolerability in routine clinical practice.
Source: NewsMedical - 🏆 19. / 71 Read more »